Characterization of the drug-to-antibody ratio distribution for antibody-drug conjugates in plasma/serum

DOI: 10.4155/bio.13.66
Bioanalysis, 2013, 5, 1057-71.

#	Paper	IF	Citations
97	Design, synthesis, and evaluation of DNA minor groove binding agents: the duocarmycins. *Pure and Applied Chemistry*, **1994**, 66, 837-844	2.1	19
96	Bioanalysis special focus issue on antibody-drug conjugates. *Bioanalysis*, **2013**, 5, 981-3	2.1	17
95	Targeting castration-resistant prostate cancer with monoclonal antibodies and constructs. *Immunotherapy*, **2013**, 5, 1347-55	3.8	4
94	PK of immunoconjugate anticancer agent CMD-193 in rats: ligand-binding assay approach to determine in vivo immunoconjugate stability. *Bioanalysis*, **2014**, 6, 21-32	2.1	12
93	Innovative native MS methodologies for antibody drug conjugate characterization: High resolution native MS and IM-MS for average DAR and DAR distribution assessment. *Analytical Chemistry*, **2014**, 86, 10674-83	7.8	130
92	Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering. *Journal of Medicinal Chemistry*, **2014**, 57, 7890-9	8.3	74
91	Measurement of in vivo drug load distribution of cysteine-linked antibody-drug conjugates using microscale liquid chromatography mass spectrometry. *Analytical Chemistry*, **2014**, 86, 3420-5	7.8	60
90	Conformation and dynamics of interchain cysteine-linked antibody-drug conjugates as revealed by hydrogen/deuterium exchange mass spectrometry. *Analytical Chemistry*, **2014**, 86, 2657-64	7.8	79
89	A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer. *AAPS Journal*, **2014**, 16, 994-1008	3.7	69
88	ADME for Therapeutic Biologics: Antibody-Derived Proteins and Proteins with Novel Scaffolds. **2015**, 1-16		
87	CBTF: new amine-to-thiol coupling reagent for preparation of antibody conjugates with increased plasma stability. *Bioconjugate Chemistry*, **2015**, 26, 197-200	6.3	47
86	Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates. *Pharmaceutical Research*, **2015**, 32, 3470-9	4.5	71
85	Utility of Ion Mobility Mass Spectrometry for Drug-to-Antibody Ratio Measurements in Antibody-Drug Conjugates. *Journal of the American Society for Mass Spectrometry*, **2015**, 26, 1791-4	3.5	24
84	Biotransformation and stability of antibody-drug conjugates: payload metabolism and linker cleavage delineation. *Bioanalysis*, **2015**, 7, 1319-23	2.1	7
83	Antibody-Drug Conjugates. *AAPS Advances in the Pharmaceutical Sciences Series*, **2015**,	0.5	6
82	Emerging formats for next-generation antibody drug conjugates. *Expert Opinion on Drug Discovery*, **2015**, 10, 463-81	6.2	48
81	Quantitative bioanalysis of antibody-conjugated payload in monkey plasma using a hybrid immuno-capture LC-MS/MS approach: Assay development, validation, and a case study. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2015**, 1002, 54-62	3.2	44

80	Bioanalysis of antibody-drug conjugates. *Bioanalysis*, **2015**, 7, 1559-60	2.1	7
79	An integrated multiplatform bioanalytical strategy for antibody-drug conjugates: a novel case study. *Bioanalysis*, **2015**, 7, 1569-82	2.1	25
78	Antibody-drug conjugates nonclinical support: from early to late nonclinical bioanalysis using ligand-binding assays. *Bioanalysis*, **2015**, 7, 1605-17	2.1	20
77	Bioanalytical approaches for characterizing catabolism of antibody-drug conjugates. *Bioanalysis*, **2015**, 7, 1583-604	2.1	26
76	Approaches to Interchain Cysteine-Linked ADC Characterization by Mass Spectrometry. *Molecular Pharmaceutics*, **2015**, 12, 1774-83	5.6	29
75	. **2016**,		4
74	Characterization of antibody-drug conjugates by mass spectrometry: advances and future trends. *Drug Discovery Today*, **2016**, 21, 850-5	8.8	33
73	Where Did the Linker-Payload Go? A Quantitative Investigation on the Destination of the Released Linker-Payload from an Antibody-Drug Conjugate with a Maleimide Linker in Plasma. *Analytical Chemistry*, **2016**, 88, 4979-86	7.8	53
72	Impact of organic modifier and temperature on protein denaturation in hydrophobic interaction chromatography. *Journal of Pharmaceutical and Biomedical Analysis*, **2016**, 131, 124-132	3.5	26
71	Calculated conjugated payload from immunoassay and LC-MS intact protein analysis measurements of antibody-drug conjugate. *Bioanalysis*, **2016**, 8, 2205-2217	2.1	18
70	A workflow for absolute quantitation of large therapeutic proteins in biological samples at intact level using LC-HRMS. *Bioanalysis*, **2016**, 8, 1679-91	2.1	49
69	Challenges and advances in the assessment of the disposition of antibody-drug conjugates. *Biopharmaceutics and Drug Disposition*, **2016**, 37, 66-74	1.7	33
68	2-(Maleimidomethyl)-1,3-Dioxanes (MD): a Serum-Stable Self-hydrolysable Hydrophilic Alternative to Classical Maleimide Conjugation. *Scientific Reports*, **2016**, 6, 30835	4.9	31
67	Unconjugated payload quantification and DAR characterization of antibody-drug conjugates using high-resolution MS. *Bioanalysis*, **2016**, 8, 1663-78	2.1	25
66	Antibody-drug conjugate characterization by chromatographic and electrophoretic techniques. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2016**, 1032, 39-50	3.2	46
65	QC Assay Development. **2016**, 131-149		
64	Bioanalytical Strategies Enabling Successful ADC Translation. **2016**, 177-205		
63	Custom-Designed Affinity Capture LC-MS F(ab')2 Assay for Biotransformation Assessment of Site-Specific Antibody Drug Conjugates. *Analytical Chemistry*, **2016**, 88, 11340-11346	7.8	47

62	RP-HPLC DAR Characterization of Site-Specific Antibody Drug Conjugates Produced in a Cell-Free Expression System. *Organic Process Research and Development*, **2016**, 20, 1034-1043	3.9	16
61	A new anti-human Fc method to capture and analyze ADCs for characterization of drug distribution and the drug-to-antibody ratio in serum from pre-clinical species. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2016**, 1032, 149-154	3.2	13
60	Antibody-drug conjugate bioanalysis using LB-LC-MS/MS hybrid assays: strategies, methodology and correlation to ligand-binding assays. *Bioanalysis*, **2016**, 8, 1383-401	2.1	24
59	Rapid quantification of a cleavable antibody-conjugated drug by liquid chromatography/tandem mass spectrometry with microwave-assisted enzymatic cleavage. *Journal of Pharmaceutical and Biomedical Analysis*, **2016**, 128, 226-235	3.5	5
58	Current Approaches for Absorption, Distribution, Metabolism, and Excretion Characterization of Antibody-Drug Conjugates: An Industry White Paper. *Drug Metabolism and Disposition*, **2016**, 44, 617-23	4	59
57	Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug conjugates. *Expert Review of Proteomics*, **2016**, 13, 157-83	4.2	78
56	Qualitative and quantitative characterization of protein biotherapeutics with liquid chromatography mass spectrometry. *Mass Spectrometry Reviews*, **2017**, 36, 734-754	11	42
55	High-Resolution Accurate-Mass Mass Spectrometry Enabling In-Depth Characterization of in Vivo Biotransformations for Intact Antibody-Drug Conjugates. *Analytical Chemistry*, **2017**, 89, 5476-5483	7.8	35
54	Protocols for the analytical characterization of therapeutic monoclonal antibodies. I - Non-denaturing chromatographic techniques. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2017**, 1058, 73-84	3.2	31
53	Simultaneous Catabolite Identification and Quantitation of Large Therapeutic Protein at the Intact Level by Immunoaffinity Capture Liquid Chromatography-High-Resolution Mass Spectrometry. *Analytical Chemistry*, **2017**, 89, 6065-6075	7.8	34
52	Mass Spectrometry-Based Methodologies for Pharmacokinetic Characterization of Antibody Drug Conjugate Candidates During Drug Development. **2017**, 183-201		1
51	The Application of Immunoaffinity-Based Mass Spectrometry to Characterize Protein Biomarkers and Biotherapeutics. **2017**, 67-89		
50	Antibodies and associates: Partners in targeted drug delivery. *Pharmacology & Therapeutics*, **2017**, 177, 129-145	13.9	45
49	A generic approach for simultaneous measurements of total antibody and cleavable antibody-conjugated drug by LC/MS/MS. *Analytical Biochemistry*, **2017**, 537, 33-36	3.1	10
48	Characterization of Antibody Drug Conjugates. **2017**, 155-168		
47	Immunoprecipitation middle-up LC-MS for in vivo drug-to-antibody ratio determination for antibody-drug conjugates. *Bioanalysis*, **2017**, 9, 1535-1549	2.1	12
46	Toward best practices in data processing and analysis for intact biotherapeutics by MS in quantitative bioanalysis. *Bioanalysis*, **2017**, 9, 1883-1893	2.1	19
45	LC MS Challenges in Characterizing and Quantifying Monoclonal Antibodies (mAb) and Antibody-Drug Conjugates (ADC) in Biological Samples. *Current Pharmacology Reports*, **2018**, 4, 45-63	5.5	13

44	LC/MS/MS Bioanalysis of Protein-Drug Conjugates-The Importance of Incorporating Succinimide Hydrolysis Products. *Analytical Chemistry*, **2018**, 90, 5314-5321	7.8	9
43	ADME Considerations and Bioanalytical Strategies for Pharmacokinetic Assessments of Antibody-Drug Conjugates. *Antibodies*, **2018**, 7,	7	18
42	Optimizing hybrid LC-MS/MS binding conditions is critical: impact of biotransformation on quantification of trastuzumab. *Bioanalysis*, **2018**,	2.1	12
41	Review of approaches and examples for monitoring biotransformation in protein and peptide therapeutics by MS. *Bioanalysis*, **2018**,	2.1	14
40	Characterization of in vivo biotransformations for trastuzumab emtansine by high-resolution accurate-mass mass spectrometry. *MAbs*, **2018**, 10, 960-967	6.6	12
39	Quantitation of intact monoclonal antibody in biological samples: comparison of different data processing strategies. *Bioanalysis*, **2018**, 10, 1055-1067	2.1	20
38	In situ quantitative bioanalysis of monomethyl auristatin E-conjugated antibody-drug conjugates by flow cytometry. *European Journal of Pharmaceutical Sciences*, **2018**, 120, 89-95	5.1	1
37	LC-HRMS quantitation of intact antibody drug conjugate trastuzumab emtansine from rat plasma. *Bioanalysis*, **2018**, 10, 851-862	2.1	28
36	Characterization of Positional Isomers of Interchain Cysteine Linked Antibody-Drug Conjugates by High-Resolution Mass Spectrometry. *Analytical Chemistry*, **2019**, 91, 8558-8563	7.8	1
35	A Modified Drift Tube Ion Mobility-Mass Spectrometer for Charge-Multiplexed Collision-Induced Unfolding. *Analytical Chemistry*, **2019**, 91, 8137-8146	7.8	17
34	Protein quantification by LC-MS: a decade of progress through the pages of. *Bioanalysis*, **2019**, 11, 629-644	2.1	33
33	Sample Preparation for LC-MS Bioanalysis of Antibody□Drug Conjugates. **2019**, 335-350		1
32	Method development of a novel PK assay for antibody-conjugated drug measurement of ADCs using peptide-linker drug analyte. *Analytical and Bioanalytical Chemistry*, **2019**, 411, 2587-2596	4.4	3
31	Multiplex LC-MS/MS Assays for Clinical Bioanalysis of MEDI4276, an Antibody-Drug Conjugate of Tubulysin Analogue Attached via Cleavable Linker to a Biparatopic Humanized Antibody against HER-2. *Antibodies*, **2019**, 8,	7	23
30	Immunoaffinity LC-MS/MS to quantify a PEGylated anti-Factor D Fab biotherapeutic in cynomolgus monkey serum. *Bioanalysis*, **2019**, 11, 2161-2173	2.1	4
29	. **2019**,		6
28	Biotherapeutic Antibody Subunit LC-MS and Peptide Mapping LC-MS Measurements to Study Possible Biotransformation and Critical Quality Attributes In□Vivo. *Journal of Pharmaceutical Sciences*, **2019**, 108, 1415-1422	3.9	5
27	Reductive Desulfuration as an Important Tool in Detection of Small Molecule Modifications to Payload of Antibody Drug Conjugates. *Analytical Chemistry*, **2019**, 91, 2368-2375	7.8	2

26	Immune modulation by curcumin: The role of interleukin-10. *Critical Reviews in Food Science and Nutrition*, **2019**, 59, 89-101	11.5	178
25	Antibody-drug conjugates: smart weapons against cancer. *Archives of Medical Science*, **2020**, 16, 1257-1262	2.9	2
24	Antibody-Drug Conjugates. *Methods in Molecular Biology*, **2020**,	1.4	0
23	LC-MS characterization of antibody-based therapeutics: recent highlights and future prospects. **2020**, 1-33		3
22	Bioanalysis of small and large molecule drugs, metabolites, and biomarkers by LC-MS. **2020**, 3-38		1
21	2-Azirines as Potential Bifunctional Chemical Linkers of Cysteine Residues in Bioconjugate Technology. *Organic Letters*, **2020**, 22, 2038-2043	6.2	9
20	IQ consortium perspective: complementary LBA and LC-MS in protein therapeutics bioanalysis and biotransformation assessment. *Bioanalysis*, **2020**, 12, 257-270	2.1	11
19	Application of middle-down approach in quantitation and catabolite identification of protein by LC-high-resolution mass spectrometry. *Bioanalysis*, **2021**, 13, 465-479	2.1	
18	Characterization of Antibody-Drug Conjugate Pharmacokinetics and in Vivo Biotransformation Using Quantitative Intact LC-HRMS and Surrogate Analyte LC-MRM. *Analytical Chemistry*, **2021**, 93, 6135-6144	7.8	7
17	Linker Design Impacts Antibody-Drug Conjugate Pharmacokinetics and Efficacy Modulating the Stability and Payload Release Efficiency. *Frontiers in Pharmacology*, **2021**, 12, 687926	5.6	8
16	High-Throughput Multi-attribute Analysis of Antibody-Drug Conjugates Enabled by Trapped Ion Mobility Spectrometry and Top-Down Mass Spectrometry. *Analytical Chemistry*, **2021**, 93, 10013-10021	7.8	5
15	Drug-to-Antibody Ratio Estimation via Proteoform Peak Integration in the Analysis of Antibody-Oligonucleotide Conjugates with Orbitrap Fourier Transform Mass Spectrometry. *Analytical Chemistry*, **2021**, 93, 12930-12937	7.8	2
14	High-Resolution Characterization of ADCs by Orbitrap LCMS. *Methods in Molecular Biology*, **2020**, 2078, 213-219	1.4	2
13	Pharmacokinetics/Pharmacodynamics and Disposition of Antibody-Drug Conjugates. *AAPS Advances in the Pharmaceutical Sciences Series*, **2015**, 117-131	0.5	1
12	Current LC-MS-based strategies for characterization and quantification of antibody-drug conjugates. *Journal of Pharmaceutical Analysis*, **2020**, 10, 209-220	14	18
11	Risk-Based Pharmacokinetic and Drug-Drug Interaction Characterization of Antibody-Drug Conjugates in Oncology Clinical Development: An International Consortium for Innovation and Quality in Pharmaceutical Development Perspective. *Clinical Pharmacology and Therapeutics*, **2021**,	6.1	3
10	Investigating the Nonclinical ADME and PK/PD of an Antibody Drug Conjugate: A Case Study of Ado-Trastuzumab Emtansine (T-DM1). 1-11		
9	Novel methods to characterize antibody drug conjugates (DAR and PK emphasis). **2015**, 70-88		

8	Introduction to Antibody-Drug Conjugates. *Antibodies*, **2021**, 10,	7	5
7	Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate.. *Journal of Pharmacokinetics and Pharmacodynamics*, **2022**,	2.7	1
6	Potential of antibody□drug conjugates (ADCs) for cancer therapy. **2022**, 22,		2
5	An Introduction to Bioanalysis of Antibody-Drug Conjugates. **2022**, 49-74		0
4	ADME and DMPK considerations for the Discovery and Development of Antibody Drug Conjugates (ADCs). 1-44		0
3	Antibody□Drug Conjugates: Development and Applications. **2022**, 127-154		0
2	Pharmacokinetics and Pharmacodynamics of Antibody-Drug Conjugates Administered via Subcutaneous and Intratumoral Routes. **2023**, 15, 1132		0
1	Software-Assisted Data Processing Workflow for Intact Glycoprotein Mass Spectrometry. **2023**, 22, 1367-1376		0